1,484 reports of this reaction
3.7% of all INSULIN GLARGINE YFGN reports
#2 most reported adverse reaction
BLOOD GLUCOSE INCREASED is the #2 most commonly reported adverse reaction for INSULIN GLARGINE YFGN, manufactured by Biocon Biologics Inc.. There are 1,484 FDA adverse event reports linking INSULIN GLARGINE YFGN to BLOOD GLUCOSE INCREASED. This represents approximately 3.7% of all 39,886 adverse event reports for this drug.
Patients taking INSULIN GLARGINE YFGN who experience blood glucose increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD GLUCOSE INCREASED is moderately reported among INSULIN GLARGINE YFGN users, representing a notable but not dominant share of adverse events.
In addition to blood glucose increased, the following adverse reactions have been reported for INSULIN GLARGINE YFGN:
The following drugs have also been linked to blood glucose increased in FDA adverse event reports:
BLOOD GLUCOSE INCREASED has been reported as an adverse event in 1,484 FDA reports for INSULIN GLARGINE YFGN. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD GLUCOSE INCREASED accounts for approximately 3.7% of all adverse event reports for INSULIN GLARGINE YFGN, making it one of the most commonly reported side effect.
If you experience blood glucose increased while taking INSULIN GLARGINE YFGN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.